differentiated antibiotics

Cempra, Inc. Receives $10 Million Milestone Payment From Toyama Chemical Co. Triggered by Solithromycin's Clinical Development Progress in Japan

CHAPEL HILL, N.C., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced the receipt of a $10 million milestone payment from Toyama Chemical Co., a subsidiary of FUJIFILM Holdings Corporation, triggered by Toyama's progress of its solithromycin clinical development program in Japan, the world's second largest antibiotic market. 


Cempra, Inc. to Present at Three Investor Conferences

CHAPEL HILL, N.C., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at three upcoming investor conferences.